⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
NATCOPHARM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | NATCOPHARM | Market Cap | 17,142 Cr. | Current Price | 958 ₹ | High / Low | 1,060 ₹ |
| Stock P/E | 11.4 | Book Value | 462 ₹ | Dividend Yield | 0.63 % | ROCE | 31.8 % |
| ROE | 27.5 % | Face Value | 2.00 ₹ | DMA 50 | 919 ₹ | DMA 200 | 912 ₹ |
| Chg in FII Hold | 1.07 % | Chg in DII Hold | -0.48 % | PAT Qtr | 107 Cr. | PAT Prev Qtr | 501 Cr. |
| RSI | 52.9 | MACD | 23.1 | Volume | 6,43,164 | Avg Vol 1Wk | 7,32,485 |
| Low price | 660 ₹ | High price | 1,060 ₹ | PEG Ratio | 0.07 | Debt to equity | 0.03 |
| 52w Index | 74.4 % | Qtr Profit Var | -14.4 % | EPS | 83.8 ₹ | Industry PE | 27.6 |
📊 Financials
- Revenue & Profitability: PAT fell from ₹501 Cr. to ₹107 Cr. (-14.4% QoQ), showing short-term weakness. EPS at ₹83.8 remains strong.
- Margins & Returns: ROCE (31.8%) and ROE (27.5%) highlight excellent efficiency and profitability.
- Debt: Debt-to-equity ratio of 0.03 → virtually debt-free, ensuring financial stability.
- Cash Flow: Strong profitability and minimal leverage support healthy cash flows.
💹 Valuation
- P/E Ratio: 11.4 vs Industry PE of 27.6 → Undervalued compared to peers.
- P/B Ratio: ~2.07 (Price ₹958 / Book Value ₹462) → Reasonable valuation.
- PEG Ratio: 0.07 → Extremely attractive, growth far exceeds valuation multiples.
- Intrinsic Value: Current price appears undervalued, offering strong upside potential.
🏢 Business Model & Competitive Advantage
- Natco Pharma operates in pharmaceuticals, focusing on niche generics, oncology, and specialty drugs.
- Competitive advantage lies in R&D strength, cost efficiency, and strong presence in regulated markets.
- Dividend yield of 0.63% is modest but adds shareholder value.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive near ₹900–940 range (close to DMA 200 at ₹912).
- Long-Term Holding: Strong candidate for long-term investors due to undervaluation, robust ROE/ROCE, and debt-free balance sheet.
✅ Positive
- Undervalued compared to industry peers (P/E 11.4 vs 27.6).
- Strong ROCE and ROE indicate efficient capital use.
- Debt-free balance sheet ensures financial safety.
- FII holdings increased (+1.07%), showing foreign investor confidence.
⚠️ Limitation
- Quarterly profit decline (-14.4%) signals near-term weakness.
- Dividend yield is modest at 0.63%.
- Stock price near 52W high (₹1,060) may limit immediate upside.
📉 Company Negative News
- PAT dropped significantly compared to previous quarter.
- DII holdings reduced (-0.48%), showing cautious domestic sentiment.
📈 Company Positive News
- FII holdings increased (+1.07%), reflecting global investor confidence.
- PEG ratio of 0.07 highlights strong growth potential.
- Technical indicators (MACD +23.1, RSI 52.9) show neutral-to-positive momentum.
🏭 Industry
- Pharmaceutical industry benefits from global demand for generics and specialty drugs.
- Industry PE at 27.6 suggests peers trade at higher valuations, making Natco Pharma attractive.
🔎 Conclusion
- Natco Pharma is fundamentally strong with excellent return ratios, debt-free balance sheet, and undervaluation compared to peers.
- Short-term profit weakness is a concern, but long-term prospects remain robust.
- Best strategy: Accumulate near ₹900–940 range for long-term holding, with potential for significant upside.